These molecular insights into the interaction between HSPB1 and tubulin led to the observation of altered tubulin acetylation in vivo, yielding HDAC6 inhibitors as a new candidate therapy for axonal CMT2 caused by HSPB1 mutations (d’Ydewalle et al. 2011). The gene discussed is HSPB1; the disease is Charcot-Marie-Tooth disease type 2.